{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50","upperLimit":"1532","value":"254"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Number of days from day 1 of treatment until date of death from any cause.","dispersionType":"Full Range","groups":[{"description":"Subjects who received Temsirolimus MTD, 20 mg/m\\^2 in Phase I of the study and all subjects in the Phase II study were included. from both Phase I and Phase II of the study are included.","id":"OG000","title":"Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"The number of analyzed participants does not include the 2 participants treated at the MTD who stopped treatment for early disease-related adverse events.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Part 2: Median Overall Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2","type":"PRIMARY","unitOfMeasure":"days"}